4SC AG año OPV
¿Qué es el año OPV de 4SC AG?
El año OPV de 4SC AG es 2005
¿Cuál es la definición de año OPV?
La oferta pública inicial es un tipo de oferta pública en la cual las acciones de una compañía generalmente se venden a inversionistas institucionales que, a su vez, venden al público en general, en una bolsa de valores, por primera vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
año OPV de compañías en Sector Health Care en XETRA en comparadas con 4SC AG
¿Qué hace 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Empresas con año opv similar a 4SC AG
- Rurelec PLC tiene año OPV de 2004
- Kona Bay Technologies tiene año OPV de 2004
- FE Investments tiene año OPV de 2004
- JBF Industries tiene año OPV de 2004
- Indiabulls Ventures tiene año OPV de 2004
- Alexion Pharmaceuticals tiene año OPV de 2004
- 4SC AG tiene año OPV de 2005
- Compass Diversified tiene año OPV de 2006
- Green Plains Inc tiene año OPV de 2006
- Catalyst Pharmaceuticals Inc tiene año OPV de 2006
- Greatland Gold Plc tiene año OPV de 2006
- Capital Environment tiene año OPV de 2006
- Athena Resources tiene año OPV de 2006